The detection of an early advanced glycation product which co-elutes with the Amadori product on aminophenylboronate affinity chromatography.

ABSTRACT

The production of an antiserum recognizing an early advanced glycation product of glycated human serum albumin (HSA) is reported. The antiserum was produced with the intention of recognizing the Amadori product, i.e. the monofructosamine derivative, of any glycated protein. In retrospect, however, the immunogen appears to have been transformed in vivo which led to the production of antibodies to an early advanced glycation product. Two-site immunometric and competitive ELISAs showed that the affinity-purified antibodies recognized glycated HSA only after it had been stored for several months. This recognition, by the antibody, was more specific for the transformed product than for the original hapten (1-amino-1-deoxy-D-fructose-6-aminohexanoic acid) used for immunization by a factor of more than 1,000. These antibodies also detected immunoreactive material present in the elution fraction after in vivo glycated HSA had been chromatographed on an aminophenylboronate affinity column, indicating that an early advanced glycation product can co-elute with the Amadori product of glycated HSA on aminophenylboronate affinity chromatography. This suggests that the antiserum recognized an early advanced glycation product that also contained cis-diols as does the Amadori product, and may prove useful in the early detection of clinical complications in diabetic patients.